Tumor Reduction with Pazopanib in a Patient with Recurrent Lumbar Chordoma

Case Reports in Oncological Medicine
Maurício Fernando Silva Almeida RibeiroRodrigo Ramella Munhoz

Abstract

Chordomas are rare malignancies of bone origin that occur in the axial skeleton, typically the skull base and lumbar/sacral regions. Although often classified as low-grade neoplasms, its locally infiltrative behavior may result in significant morbidity and mortality. Optimal surgical resection may be curative, but up to 50% of the cases relapse within 5 years, and currently there are no systemic treatments approved in this setting. A large proportion of these tumors express stem-cell factor receptor (c-KIT) and platelet-derived growth factor receptors (PDGFRs), providing a rationale for the use of tyrosine-kinase inhibitors (TKIs). A 27-year-old male presented with recurrent chordoma of the lumbar spine 4 years after initial diagnosis. Salvage therapies in the interval included repeat resections and radiation therapy. He ultimately developed multifocal recurrence not amenable to complete excision or reirradiation. A comprehensive genomic profiling assay was performed and revealed nondrugable alterations. Decision was made to proceed with systemic treatment with pazopanib 800 mg/day, resulting in tumor reduction (-23.1% reduction in size) and prolonged disease control. For this patient with a multiple recurrent chordoma and limi...Continue Reading

References

Sep 17, 2004·Cancer·Paolo G CasaliSilvana Pilotti
May 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael C HeinrichUNKNOWN Imatinib Target Exploration Consortium Study B2225
Sep 30, 2008·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Gerard J OakleyRaja R Seethala
May 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suzanne GeorgeMary L Keohan
Jul 3, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S StacchiottiP G Casali
Feb 4, 2012·The Lancet Oncology·Brian P WalcottManuel J Ferreira
Feb 15, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Silvia StacchiottiPaolo Giovanni Casali
Apr 6, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S StacchiottiP G Casali
Jan 25, 2014·Acta Oncologica·T AsklundR Henriksson
Sep 12, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·UNKNOWN ESMO/European Sarcoma Network Working Group
Feb 16, 2015·Critical Reviews in Oncology/hematology·Loïc LebellecNicolas Penel
Jun 23, 2015·Therapeutics and Clinical Risk Management·Salvatore Di MaioRobert C Rostomily
Jul 24, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E BompasN Penel
Oct 24, 2015·Current Reviews in Musculoskeletal Medicine·Xin SunJoseph H Schwab
Jan 7, 2016·Journal of Neuropathology and Experimental Neurology·Arnault Tauziéde-EspariatHoma Adle-Biassette
Nov 9, 2016·Clinical Sarcoma Research·Astrid LipplaaHans Gelderblom
Feb 12, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S StacchiottiJ Sommer
May 10, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Loïc LebellecOlivier Mir
Dec 9, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeremy S Whelan, Lara E Davis
Jul 1, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S StacchiottiP G Casali

❮ Previous
Next ❯

Citations

Feb 19, 2019·Frontiers in Oncology·Tong MengLiming Cheng

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
surgical resection
total resection
surgical resections

Clinical Trials Mentioned

NCT02383498
NCT02989636

Software Mentioned

FoundationOne®Heme

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Related Papers

The Oncologist
Rashmi ChughLaurence H Baker
The Eurasian Journal of Medicine
Saurabh RohatgiKatherine M Krajewski
Expert Opinion on Therapeutic Targets
Mohamad BydonZiya L Gokaslan
© 2022 Meta ULC. All rights reserved